Loading stock data…
BioMarin Pharmaceutical Inc. (BMRN)
$57.67-1.33 (-2.25%)
After Hours$57.70+0.03 (+0.05%)· Last close Jun 29
BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
BioMarin Pharmaceutical Inc. in the Healthcare sector is trading at $57.67 with a market capitalization of $10.6B. Wall Street consensus targets $87.85 (26 analysts), implying a +52.3% move over the next 12 months. The stock is currently 13% below its 52-week high of $66.28, remaining 3.6% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 85/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +52.3% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $766.21M↓ | $874.57M↑ | $776.13M↓ | $825.41M↑ | $745.14M |
| Gross Profit | $571.21M↓ | $598.86M↓ | $636.05M↓ | $675.32M↑ | $593.59M |
| Operating Income | $129.63M↑ | -$44.60M↑ | -$46.68M↓ | $276.87M↑ | $223.91M |
| Net Income | $105.53M↑ | -$46.57M↓ | -$30.74M↓ | $240.53M↑ | $185.69M |
Peer Comparison
JNJUNHPFE
Fundamentals
BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Paci...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$10.56B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
39.32
Beta
Defensive asset. Lower volatility than the S&P 500.
0.23
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
4.33%
Volume
Today's trading volume
1.71M
Recent News
2 Cash-Heavy Stocks with Exciting Potential and 1 We Ignore
A surplus of cash can mean financial stability, but it can also indicate a reluctance (or inability) to invest in growth. Some of these companies also face challenges like stagnating revenue, declining market share, or limited scalability.
2 Healthcare Stocks for Long-Term Investors and 1 We Brush Off
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Those leading the charge have not only realized strong financial performance but also propelled the broader industry’s returns as healthcare stocks have gained 9.5% over the past six months while the S&P 500 was up 6.2%.
Therapeutics Stocks Q1 Teardown: BioMarin Pharmaceutical (NASDAQ:BMRN) Vs The Rest
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at BioMarin Pharmaceutical (NASDAQ:BMRN) and the best and worst performers in the therapeutics industry.
ABCELLERA BIOLG (ABCL) Surges 7.1%: Is This an Indication of Further Gains?
ABCELLERA BIOLG (ABCL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
BioMarin (BMRN) Presents Positive Phase 2 Data for VOXZOGO in Hypochondroplasia Treatment
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is one of the most promising stocks with highest upside potential. On June 16, BioMarin presented new clinical data at ENDO 2026, highlighting progress in its treatments for skeletal dysplasias. An investigator-led Phase 2 extension study showed that three years of treatment with VOXZOGO (vosoritide) resulted in sustained improvements in annualized […]